USANA Health Sciences, Inc. (USNA)

Several events have impacted USANA Health Sciences' stock price in the past six months. The company reported its Q3 2025 earnings on October 22, 2025, with an EPS of -$0.15, missing the consensus estimate of $0.47, and quarterly revenue was $213.67 million, also below analyst estimates. This resulted in a net loss of -$6.5 million in Q3 2025, a significant decline from net earnings of $10.6 million in Q3 2024, and a 44% year-over-year drop in Adjusted EBITDA to $13.8 million. In Q3 2025, USANA rolled out an enhanced Brand Partner compensation plan, a strategic move aimed at stabilizing direct selling performance, however, this was linked to softer sales activity and a significant drop in active customer counts in the direct selling channel. The company's stock price has experienced a decline, with a -5.28% fall in the 10 days leading up to February 6, 2026. Over the past year, USANA Health Sciences has delivered a -44.24% change, with its 52-week range between $18.48 and $38.32. As of January 30, 2026, the share price was $21.70, representing a decline of 31.42% from February 3, 2025, when it was $31.64. On January 8, 2026, Kevin Guest returned to USANA Health Sciences as CEO.

While USANA Health Sciences monitors seasonal commodity markets to manage costs and supply risks, specific information regarding the seasonality of demand for its products and services is not explicitly detailed. The company's direct selling model and diverse product portfolio might suggest a relatively stable demand throughout the year, though specific product categories could experience seasonal fluctuations. However, without explicit data, this remains an inference.

USANA Health Sciences, Inc. is a publicly traded direct-selling company specializing in nutrition, personal health, and wellness products, operating within the Medical sector, specifically in the Drugs and Nutritional Supplements industry. Founded in 1992, USANA develops and manufactures high-quality, science-based nutritional, personal care, and skincare products with a focus on promoting long-term health and wellness. USANA's major product lines include core vitamin and mineral supplements utilizing proprietary InCelligence Technology, targeted supplements addressing specific health needs, clean-label, chewable children's vitamins and supplements through a DTC subsidiary, a comprehensive skincare system alongside low-glycemic meal replacement shakes and snack bars, and products like Reset meal replacement shakes, protein bars, and Rev3 energy drinks.

USANA Health Sciences has a global presence, operating in 24 markets worldwide. Mainland China is the company's largest market and its single largest source of revenue, accounting for approximately 42.7% of net sales and 41.6% of active customers in 2021. The company distributes its products across various regions, including the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. USANA announced plans to expand into India in the second half of 2023, increasing its global footprint to 25 markets.

USANA is internationally recognized for its high-quality, science-based nutritional supplements, healthy foods, and personal care products. The company maintains a strong focus on in-house research and development (R&D) to ensure its products are science-based, investing approximately $25 million in R&D in fiscal year 2024. USANA has been recognized as the No. 1 dietary supplements brand in the Philippines for seven consecutive years (2019-2025). Key events that have affected USANA's reputation in the past year include the acquisition of Hiya Health Products, the rollout of an enhanced Brand Partner compensation plan, and the launch of Next-Gen Celavive Skincare.

The ownership structure of USANA Health Sciences, Inc. shows a significant concentration, with insiders holding a substantial stake. As of November 2025, insiders held 41.07% of the company, including founder Dr. Myron Wentz. Institutional investors are the primary holders of USANA Health Sciences stock, representing 57.88% of ownership as of March 31, 2025. Major institutional owners include BlackRock, Inc., Pzena Investment Management LLC, Renaissance Technologies LLC, and The Vanguard Group, Inc. Other notable institutional holders include Dimensional Fund Advisors LP, State Street Corp, Morgan Stanley, and Charles Schwab Investment Management Inc.